Silver-Russell Syndrome Market

Market Overview:

The Silver-Russell syndrome market reached a value of USD 393.6 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 638.4 Million by 2035, exhibiting a growth rate (CAGR) of 4.50% during 2025-2035.

The Silver-Russell syndrome market has been comprehensively analyzed in IMARC's new report titled "Silver-Russell Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Silver-Russell syndrome is an uncommon condition marked by slow development before and after birth. Babies with this illness usually have a low birth weight and do not grow or acquire weight at the expected rate (failure to thrive). Head growth is normal; however, the head may appear larger than the rest of the body. Affected children experience repeated episodes of low blood sugar. Gastrointestinal issues such as vomiting and stomach acid backflow into the esophagus (known as gastroesophageal reflux or GERD) are also frequent. Adults suffering from Silver-Russell syndrome are often shorter than the general population and are more likely to develop metabolic issues such as type 2 diabetes. Additional skeletal abnormalities may include atypical curling of the fifth finger, short fingers, and an abnormal curvature of the spine. The diagnostic evaluation of this condition is based on a comprehensive medical history, along with a physical exam. The healthcare professional might recommend genetic testing to identify specific genetic and epigenetic abnormalities in patients.

The escalating prevalence of genetic changes in chromosomes 7 and 11, which particularly involve imprinted genes and methylation patterns, leading to disrupted regulation of growth-related genes, is primarily driving the Silver-Russell syndrome market. In addition to this, the inflating utilization of gonadotropin-releasing hormone (GnRH) analogues that can delay the progression of puberty and potentially preserve adult height potential is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapy on account of its several advantages, such as improved muscle tone, enhanced sensory regulation, and boosted independence, is further bolstering the market growth. Apart from this, the rising usage of whole-genome sequencing (WGS) method, since it identifies rare single-gene mutations that may contribute to the underlying symptoms, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which involves correcting the underlying genetic defects or modulating the expression of genes involved in growth and development, is expected to drive the Silver-Russell syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Silver-Russell syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Silver-Russell syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Silver-Russell syndrome market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Silver-Russell syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Silver-Russell syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Silver-Russell syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Silver-Russell syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Silver-Russell syndrome market across the seven major markets in 2024and what will it look like in 2035?
• What is the growth rate of the Silver-Russell syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of Silver-Russell syndrome across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Silver-Russell syndrome by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Silver-Russell syndrome by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with Silver-Russell syndrome across the seven major markets?
• What is the size of the Silver-Russell syndrome patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Silver-Russell syndrome?
• What will be the growth rate of patients across the seven major markets?

Silver-Russell Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Silver-Russell syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Silver-Russell syndrome market?
• What are the key regulatory events related to the Silver-Russell syndrome market?
• What is the structure of clinical trial landscape by status related to the Silver-Russell syndrome market?
• What is the structure of clinical trial landscape by phase related to the Silver-Russell syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Silver-Russell syndrome market?